FDA Needs To Put Meaning Behind “Clinically Meaningful,” Lipicky Says
FDA's increasing requirements for clinical meaningfulness in efficacy measures make it more difficult to predict the agency's regulatory actions, former division director Ray Lipicky says
You may also be interested in...
Progression-free survival is an acceptable basis for accelerated approval of ovarian cancer agents, so long as trials are powered for survival, panelists at FDA's April 26 Ovarian Cancer Endpoint Workshop in Bethesda, Md. said
Sponsors of oncology agents should select endpoints where a drug is likely to have a "magnitude of effect" instead of focusing on survival, FDA said following its Dec. 20 approval of Bayer/Onyx' kidney cancer therapy Nexavar (sorafenib)
A two-hour pain-free response endpoint should be the primary measure of efficacy for migraine drugs, members of FDA's Peripheral & Central Nervous System Drugs Advisory Committee suggested Aug. 4